Scancell Holdings plc has entered into a research collaboration agreement with BioNTech as the two look to develop innovative T-cell therapies for the treatment of cancer. The research collaboration will combine Scancell's Moditope immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterization of naturally selected T cell receptors.